547 related articles for article (PubMed ID: 26549336)
41. Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy.
Niedoszytko M; de Monchy J; van Doormaal JJ; Jassem E; Oude Elberink JN
Allergy; 2009 Sep; 64(9):1237-45. PubMed ID: 19627278
[TBL] [Abstract][Full Text] [Related]
42. Serum concentration of baseline mast cell tryptase: evidence for a decline during long-term immunotherapy for Hymenoptera venom allergy.
Dugas-Breit S; Przybilla B; Dugas M; Arnold A; Pfundstein G; Küchenhoff H; Ruëff F
Clin Exp Allergy; 2010 Apr; 40(4):643-9. PubMed ID: 20100187
[TBL] [Abstract][Full Text] [Related]
43. Venom immunotherapy in patients with allergic reactions to insect stings.
Incorvaia C; Mauro M; Gritti BL; Makri E; Ridolo E
Expert Rev Clin Immunol; 2018 Jan; 14(1):53-59. PubMed ID: 29202591
[TBL] [Abstract][Full Text] [Related]
44. Follow-up of venom immunotherapy (VIT) based on conventional techniques and monitoring of immunoglobulin E to individual venom allergens.
Carballada F; Boquete M; Núñez R; Lombardero M; de la Torre F
J Investig Allergol Clin Immunol; 2010; 20(6):506-13. PubMed ID: 21243935
[TBL] [Abstract][Full Text] [Related]
45. Gene expression analysis in predicting the effectiveness of insect venom immunotherapy.
Niedoszytko M; Bruinenberg M; de Monchy J; Wijmenga C; Platteel M; Jassem E; Oude Elberink JN
J Allergy Clin Immunol; 2010 May; 125(5):1092-7. PubMed ID: 20334904
[TBL] [Abstract][Full Text] [Related]
46. Honeybee and wasp venom allergy: Sensitization and immunotherapy.
Adib-Tezer H; Bayerl C
J Dtsch Dermatol Ges; 2018 Oct; 16(10):1228-1247. PubMed ID: 30300499
[TBL] [Abstract][Full Text] [Related]
47. Analysis of the burden of treatment in patients receiving an EpiPen for yellow jacket anaphylaxis.
Oude Elberink JN; van der Heide S; Guyatt GH; Dubois AE
J Allergy Clin Immunol; 2006 Sep; 118(3):699-704. PubMed ID: 16950290
[TBL] [Abstract][Full Text] [Related]
48. Possible circadian variation of serum mast cell tryptase concentration.
Dugas-Breit S; Przybilla B; Schöpf P; Ruëff F
Allergy; 2005 May; 60(5):689-92. PubMed ID: 15813817
[TBL] [Abstract][Full Text] [Related]
49. The safety and efficacy of immunotherapy with aluminum hydroxide-adsorbed venom extract of Vespula spp. An open, retrospective study.
Poli F; Longo G; Parmiani S
Allergol Immunopathol (Madr); 2001; 29(5):191-6. PubMed ID: 11720652
[TBL] [Abstract][Full Text] [Related]
50. Sublingual immunotherapy with venom for patients with Hymenoptera venom allergy.
Patriarca G; Nucera E; Roncallo C; Aruanno A; Lombardo C; Decinti M; Pascolini L; Milani M; Buonomo A; Schiavino D
J Allergy Clin Immunol; 2009 Aug; 124(2):385; author reply 385-6. PubMed ID: 19482349
[No Abstract] [Full Text] [Related]
51. Outcome survey of insect venom allergic patients with venom immunotherapy in a rural population.
Roesch A; Boerzsoenyi J; Babilas P; Landthaler M; Szeimies RM
J Dtsch Dermatol Ges; 2008 Apr; 6(4):292-7. PubMed ID: 18042250
[TBL] [Abstract][Full Text] [Related]
52. [Wasp and bee venom allergy].
Knulst AC; de Maat-Bleeker F; Bruijnzeel-Koomen CA
Ned Tijdschr Geneeskd; 1998 Apr; 142(16):889-92. PubMed ID: 9623183
[TBL] [Abstract][Full Text] [Related]
53. Safety of specific immunotherapy using an ultra-rush induction regimen in bee and wasp allergy.
Bożek A; Kołodziejczyk K
Hum Vaccin Immunother; 2018 Feb; 14(2):288-291. PubMed ID: 29106324
[TBL] [Abstract][Full Text] [Related]
54. Safety and efficacy of a 12-week maintenance interval in patients treated with Hymenoptera venom immunotherapy.
Kochuyt AM; Stevens EA
Clin Exp Allergy; 1994 Jan; 24(1):35-41. PubMed ID: 8156444
[TBL] [Abstract][Full Text] [Related]
55. Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis.
González de Olano D; Alvarez-Twose I; Esteban-López MI; Sánchez-Muñoz L; de Durana MD; Vega A; García-Montero A; González-Mancebo E; Belver T; Herrero-Gil MD; Fernández-Rivas M; Orfao A; de la Hoz B; Castells MC; Escribano L
J Allergy Clin Immunol; 2008 Feb; 121(2):519-26. PubMed ID: 18177694
[TBL] [Abstract][Full Text] [Related]
56. Rush Venom Immunotherapy in Children.
Confino-Cohen R; Rosman Y; Goldberg A
J Allergy Clin Immunol Pract; 2017; 5(3):799-803. PubMed ID: 27914814
[TBL] [Abstract][Full Text] [Related]
57. Treatment of Hymenoptera venom allergy: an update.
Pesek RD; Lockey RF
Curr Opin Allergy Clin Immunol; 2014 Aug; 14(4):340-6. PubMed ID: 24887986
[TBL] [Abstract][Full Text] [Related]
58. [Sting challenge: indications and execution].
Ruëff F; Przybilla B
Hautarzt; 2014 Sep; 65(9):796-801. PubMed ID: 25234628
[TBL] [Abstract][Full Text] [Related]
59. Venom immunotherapy (VIT): clinical efficacy and improvement in quality of life.
Oude Elberink J
Drugs Today (Barc); 2008 Dec; 44 Suppl B():43-5. PubMed ID: 19221618
[No Abstract] [Full Text] [Related]
60. Insect Venom Immunotherapy: Analysis of the Safety and Tolerance of 3 Buildup Protocols Frequently Used in Spain.
Gutiérrez Fernández D; Moreno-Ancillo A; Fernández Meléndez S; Domínguez-Noche C; Gálvez Ruiz P; Alfaya Arias T; Carballada González F; Alonso Llamazares A; Marques Amat L; Vega Castro A; Antolín Amérigo D; Cruz Granados S; Ruiz León B; Sánchez Morillas L; Fernández Sánchez J; Soriano Gomis V; Borja Segade J; Dalmau Duch G; Guspi Bori R; Miranda Páez A
J Investig Allergol Clin Immunol; 2016; 26(6):366-373. PubMed ID: 27996943
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
